Elefante Mark B Acquires 463 Shares of Danaher Corporation $DHR

Elefante Mark B boosted its holdings in Danaher Corporation (NYSE:DHR) by 2.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,112 shares of the conglomerate’s stock after acquiring an additional 463 shares during the quarter. Danaher accounts for approximately 2.8% of Elefante Mark B’s investment portfolio, making the stock its 16th biggest holding. Elefante Mark B’s holdings in Danaher were worth $3,775,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. MGO One Seven LLC lifted its position in Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after acquiring an additional 20,813 shares in the last quarter. Chicago Capital LLC lifted its position in shares of Danaher by 11.6% during the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after buying an additional 1,391 shares in the last quarter. UniSuper Management Pty Ltd lifted its position in shares of Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after buying an additional 2,667 shares in the last quarter. Asahi Life Asset Management CO. LTD. bought a new position in shares of Danaher during the 1st quarter worth approximately $539,000. Finally, Horizon Financial Services LLC lifted its position in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock worth $1,681,000 after buying an additional 8,160 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 1.4%

Shares of DHR stock opened at $205.36 on Tuesday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.41. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The firm’s 50 day moving average is $200.82 and its 200 day moving average is $197.06. The stock has a market capitalization of $147.05 billion, a P/E ratio of 43.69, a P/E/G ratio of 2.88 and a beta of 0.77.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same quarter last year, the company posted $1.72 earnings per share. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 11.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Rothschild Redb cut shares of Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Robert W. Baird boosted their price target on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research report on Friday, July 18th. Bank of America cut their target price on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Finally, Guggenheim restated a “buy” rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $244.60.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.